Elizabeth Eisenhauer

Elizabeth Eisenhauer is a Canadian oncologist who spent a large portion of her career undertaking phase I and II trials of novel cancer therapies through her role as Director of the Investigational New Drug Program in the Canadian Cancer Trials Group.[1][2] She received her Doctor of Medicine degree from Queen's University[1] and was trained in internal medicine and hematology, obtaining fellowships from the Royal College of Physicians and Surgeons of Canada.[2]

Eisenhauer is an Emerita professor in the Department of Oncology at Queen's University in Kingston ON Canada, and was Department Head from 2012-2017.[2][1] She has served on the Board of the American Society of Clinical Oncology, [[National Cancer Institute of Canada (as its President), the European Organization for Research and Treatment of Cancer, and the Canadian Cancer Society.[2][3]

In 2012, she was awarded with the Queen Elizabeth II Diamond Jubilee medal for “her tremendous commitment to the advancement of cancer therapy, supportive care and prevention across Canada and internationally.”[1] In 2015 she was elected as a fellow of the Royal Society of Canada[1][4] and in 2017, she was inducted as an Officer of the Order of Canada.[1]  

References
  1. "Elizabeth Eisenhauer | KGH Kingston General Hospital". www.kgh.on.ca. Retrieved 2019-05-23.
  2. "Elizabeth Eisenhauer". www.ctg.queensu.ca. Retrieved 2019-05-23.
  3. "Dr. Elizabeth A. Eisenhauer | Congress". www.worldcancercongress.org. Retrieved 2019-05-23.
  4. "Search Fellows | The Royal Society of Canada". src-rsc.com. Retrieved 2019-05-23.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.